微信关注
China
Total item
Cart Subtotal
￥ 0.00 “EGFR”的搜索结果
-
PD168393
Catalog No. A12725 -
DM1-SMCC
Catalog No. A15955 -
ZM 39923 HCl
Catalog No. A13509 JAK3 抑制剂ZM 39923 HCl是JAK3抑制剂（IC50 = 79 nM），其抑制表皮生长因子受体，JAK1和细胞周期蛋白依赖性激酶4（IC50s分别为2.4、40和10 M）的抑制作用较小。 了解更多 -
Poziotinib
Catalog No. A13044 EGFR 抑制剂Poziotinib是一种口服生物利用的，基于喹唑啉的泛表皮生长因子受体（EGFR或HER）抑制剂，具有潜在的抗肿瘤活性。 了解更多 -
ARRY-543 (Varlitinib, ASLAN001)
Catalog No. A12868 ErbB 抑制剂ARRY-543 (Varlitinib,ASLAN001)是一种新型口服ErbB家族抑制剂，与批准的ErbB抑制剂不同，它直接或间接靶向ErbB家族的所有成员，包括ErbB3，在治疗通过多个ErbB家族成员发出信号的肿瘤方面具有潜在优势。 了解更多 -
AG-17
Catalog No. A11949 -
BIBX 1382
Catalog No. A11334 -
ARRY334543 (Varlitinib)
Catalog No. A11158 EGFR 抑制剂ARRY334543 (Varlitinib)是一种有效的EGFR和ErbB-2口服活性小分子抑制剂。 了解更多 -
XL647 (Tesevatinib)
Catalog No. A11057 EGFR, HER2 and VEGFR 抑制剂XL647 (Tesevatinib)是一种口服生物可利用的小分子RTK抑制剂，可结合并抑制在肿瘤细胞增殖和肿瘤血管形成中起主要作用的几种酪氨酸受体激酶，包括EGFR，HER2，ERBB2，VEGFR和EphB4。 了解更多 -
Chrysophanic acid (Chrysophanol)
Catalog No. A10210 -
AEE788
Catalog No. A10043 -
BMS 599626 (AC480)
Catalog No. A11209 EGFR 抑制剂BMS 599626 (AC480)是一种选择性的，高效效的HER1，HER2和HER4酪氨酸激酶抑制剂（IC50分别为22、32和190 nM），具有潜在的抗肿瘤活性。 了解更多 -
PD153035 (HCl salt)
Catalog No. A10702 -
WZ3146
Catalog No. A10990 -
WZ8040
Catalog No. A10992 -
CUDC-101
Catalog No. A10246 -
AG-1478 (Tyrphostin AG-1478)
Catalog No. A11022 EGFR 抑制剂AG-1478 (Tyrphostin AG-1478)是EGFR激酶的抑制剂，IC50值为3 nM。 了解更多 -
AZD8931 (Sapitinib)
Catalog No. A10116 pan-EGFR/pan-erbB 抑制剂AZD8931 (Sapitinib)是ErbB1，ErbB2和ErbB3受体信号传导的等效抑制剂。 了解更多 -
PD 0332991 HCl (Palbociclib)
Catalog No. A10701 CDK 4/6 抑制剂PD 0332991 HCl (Palbociclib)是一种高度选择性的CDK4/6抑制剂，它对CDK1/2/5，EGFR，FGFR，PDGFR，InsR等没有抑制活性，具有潜在的抗肿瘤活性。 了解更多 -
Pelitinib (EKB-569)
Catalog No. A10706 EGFR 抑制剂Pelitinib (EKB-569)是一种有效的,不可逆EGFR抑制剂,IC50为38.5 nM 了解更多 -
JNJ-38158471
Catalog No. A22345 VEGFR-2 inhibitorJNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC50s of 180 and 500 nM, respectively. 了解更多 -
ZM323881 hydrochloride
Catalog No. A22392 VEGFR2 inhibitorZM323881 hydrochloride is a potent and selective VEGFR2 inhibitor with an IC50 of less than 2 nM. 了解更多 -
CP-547632 hydrochloride
Catalog No. A22019 VEGFR-2/FGFR inhibitorCP-547632 hydrochloride is a well-tolerated, orally-bioavailable inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases with IC50s of 11 nM and 9 nM, respectively. 了解更多 -
Sulfatinib
Catalog No. A21915 tyrosine kinase inhibitorSulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM. 了解更多 -
Vatalanib free base
Catalog No. A21871 VEGFR2/KDR inhibitorVatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM. 了解更多 -
Cediranib maleate
Catalog No. A21857 VEGFR inhibitorCediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. 了解更多 -
ENMD-2076 Tartrate
Catalog No. A21583 multi-targeted kinase inhibitorENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. 了解更多 -
Sorafenib (D4)
Catalog No. A21495 multikinase inhibitorSorafenib D4 (Bay 43-9006 D4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. 了解更多 -
Sorafenib (D3)
Catalog No. A21489 multikinase inhibitorSorafenib D3 (Bay 43-9006 D3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. 了解更多 -
TAS-115 mesylate
Catalog No. A21389 c-Met/HGFR inhibitorTAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. 了解更多 -
VEGFR-2-IN-5
Catalog No. A20896 VEGFR2 inhibitorVEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 31. 了解更多 -
Lenvatinib mesylate
Catalog No. A17567 multi-targeted tyrosine kinase inhibitorLenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. 了解更多
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
FILTER BY:
购物选项
- 分类
-
- Epigenetics (10)
- Apoptosis (4)
- PI3K / Akt / mTOR (4)
- Protein Tyrosine Kinases (188)
- Angiogenesis (185)
- MAPK (9)
- JAK / Stat (95)
- Cell Cycle (7)
- DNA Damage (2)
- Cell Metabolism (1)
- NF-kB/IkB (1)
- TGF-β / Smad (2)
- PROTACs (1)
- Natural Products (2)
- Ready to Use Solution (64)
- Products On Sale (71)
- Monoclonal Antibodies (2)
- Enzymes (6)
- 作用机制
-
- Inhibitor (抑制剂) (211)
- Antagonist (拮抗剂) (1)
- Activator (激活剂) (1)
- 靶点
-
- Abl (3)
- Aurora A (5)
- Aurora B (3)
- Aurora C (2)
- B-Raf (4)
- C-Raf (Raf-1) (2)
- CDK2 (2)
- CDK4 (1)
- Chk2 (1)
- CSF1R (3)
- EGFR (24)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- EphB4 (1)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FGFR (1)
- FGFR1 (15)
- FGFR2 (4)
- FGFR3 (5)
- FGFR4 (2)
- FLT3 (4)
- HDAC (1)
- HER2 (2)
- JAK1 (2)
- JAK2 (1)
- JAK3 (2)
- Kit (8)
- Lck (1)
- Lyn (1)
- PDGFRα (5)
- PDGFRβ (12)
- RET (4)
- Src (2)
- TrkA (1)
- VEGFR1 (FLT1) (12)
- VEGFR2 (FLK1) (25)
- VEGFR3 (FLT4) (11)
ADOOQ 产品质量保证
We promise all products to perform as described.